-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW) Short Interest Update
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW) Short Interest Update
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) was the recipient of a large drop in short interest in November. As of November 30th, there was short interest totalling 15,000 shares, a drop of 14.3% from the November 15th total of 17,500 shares. Based on an average daily volume of 51,100 shares, the days-to-cover ratio is currently 0.3 days.
Institutional Investors Weigh In On Comera Life Sciences
A hedge fund recently bought a new stake in Comera Life Sciences stock. Warberg Asset Management LLC bought a new position in Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 202,000 shares of the company's stock, valued at approximately $29,000.
Get Comera Life Sciences alerts:Comera Life Sciences Stock Performance
NASDAQ CMRAW remained flat at $0.06 during mid-day trading on Friday. The company's stock had a trading volume of 3 shares, compared to its average volume of 165,797. Comera Life Sciences has a 12-month low of $0.03 and a 12-month high of $0.70. The firm's fifty day moving average price is $0.06.
About Comera Life Sciences
(Get Rating)Comera Life Sciences Holdings, Inc, a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
See Also
- Get a free copy of the StockNews.com research report on Comera Life Sciences (CMRAW)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) was the recipient of a large drop in short interest in November. As of November 30th, there was short interest totalling 15,000 shares, a drop of 14.3% from the November 15th total of 17,500 shares. Based on an average daily volume of 51,100 shares, the days-to-cover ratio is currently 0.3 days.
科美拉生命科學控股公司(納斯達克代碼:CMRAW-GET Rating)是空頭股數11月份股價大幅下跌的接受者。截至11月30日,空頭股數共有15,000股,較11月15日的17,500股下降了14.3%。以日均成交量51,100股計算,目前天數與回補比率為0.3天。
Institutional Investors Weigh In On Comera Life Sciences
機構投資者看好科美拉生命科學
A hedge fund recently bought a new stake in Comera Life Sciences stock. Warberg Asset Management LLC bought a new position in Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 202,000 shares of the company's stock, valued at approximately $29,000.
一家對沖基金最近購買了科美拉生命科學公司的新股。根據華伯格資產管理公司在最近提交給美國證券交易委員會的檔案中,該公司在第二季度購買了科梅拉生命科學控股公司(納斯達克:CMRAW-GET Rating)的一個新頭寸。該公司購買了20.2萬股該公司股票,價值約2.9萬美元。
Comera Life Sciences Stock Performance
科美拉生命科學類股表現
NASDAQ CMRAW remained flat at $0.06 during mid-day trading on Friday. The company's stock had a trading volume of 3 shares, compared to its average volume of 165,797. Comera Life Sciences has a 12-month low of $0.03 and a 12-month high of $0.70. The firm's fifty day moving average price is $0.06.
在週五午盤交易中,納斯達克CMRAW持平於0.06美元。該公司股票的交易量為3股,而其平均成交量為165,797股。Comera Life Sciences的股價為0.03美元,為12個月低點,12個月高位為0.70美元。該公司的50日移動均線價格為0.06美元。
About Comera Life Sciences
科美拉生命科學公司簡介
Comera Life Sciences Holdings, Inc, a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
Comera生命科學控股公司是一家臨床前階段的生命科學公司,該公司開發了一個內部專有療法組合,其中納入了其專有配方平臺Sqore。其Sqore平臺旨在實現靜脈(IV)生物製品到皮下(SQ)製劑的轉換。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Comera Life Sciences (CMRAW)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- 免費獲取StockNews.com關於Comera生命科學的研究報告(CMRAW)
- MarketBeat:回顧一週12/12-12/16
- 哪兩家藍籌科技公司提高了他們的指引?
- 你應該擔心埃隆·馬斯克出售他持有的特斯拉股票嗎?
- 拖拉機庫存能否突破杯柄收購點?
- 現在不是購買Lennar的時候,但時機即將到來
Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Comera生命科學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Comera生命科學和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧